Roche Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) and CapitalBio have announced their

intention to initiate a strategic partnership targeting molecular diagnostic applications and the

development of technologies to fill the unmet needs of researchers worldwide. This new

development builds on the genomics and diagnostics expertise of the two companies and will focus

on furthering microarray technologies and complementary products for molecular diagnostic

applications.

“This agreement is a significant step for Roche in forming closer relations with China’s premier

biochip development company”, said Dr. Manfred Baier, Head of Roche Applied Science “The

agreement formalizes a closer relationship with CapitalBio, formed since it joined the Roche

NimbleGen Certified Service Provider (CSP) Program in January 2010.”

“CapitalBio and Roche offer a large number of complementary skills and interests which can be well

served through the harnessing of the capabilities of both companies for product research and

development, manufacturing, marketing and distribution in China and for international markets”

said Professor Jing Cheng, CEO of CapitalBio.

The partnership plans to focus initially on the research and development of instruments and

products to enhance and automate the Roche NimbleGen microarray workflow and the application

of this workflow in preventive and personalized diagnostics.

CapitalBio has recently established an Independent Medical Testing Laboratory in Chengdu, China

and has expanded its Microarray Genomics Service Facility at its Beijing headquarters. This

partnership plans closer cooperation and collaboration across a broad range of advanced molecular

diagnostic assays for clinical diagnostics and medical research, including the use of 454 Life

Sciences’ Next-Generation Sequencing for medical services.

Special focus shall be placed on cooperation in education on the benefits and use of molecular

diagnostics that exploit novel technologies involving microarrays and their related products and

next-generation sequencing in both the greater China and international markets. The partnership

also plans to establish educational facilities across China for molecular R&D and the application of

clinical molecular diagnostics.

“The partners plan to cooperate in marketing products in the greater China and international

markets”, said Fatt-Heng Wong, General Manager of Roche Diagnostics Shanghai Ltd..

Details of the agreement were not released.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with

combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech

company with truly differentiated medicines in oncology, virology, inflammation, metabolism and

CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a

pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing

medicines and diagnostic tools that enable tangible improvements in the health, quality of life and

survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10

billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United

States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai

Pharmaceutical, Japan. For more information: www.roche.com.

About CapitalBio

Headquartered in Beijing, CapitalBio Corporation is China’s leading developer and marketer of

diagnostic biochips, microarray related instruments and microarray services. Its range of LuxScan

laser confocal microarray scanners, microarray spotters and related microarray workflow

instruments are used widely in many countries. Its active biochips for cell biology studies and

dedicated software for data analysis and biomedical data management are also being used

increasingly for clinical studies, including oncology studies. The company, founded in 2000, is

closely linked to the National Engineering Research Centre for Beijing BioChip Technology. Visit

www.capitalbio.com for more information.

For life science research only. Not for use in diagnostic procedures.

454, 454 LIFE SCIENCES and NIMBLEGEN are trademarks of Roche.

Other brands or product names are trademarks of their respective holders.